Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • wearables

    - PMLiVE

    J&J’s Darzalex recommended by CHMP to treat smouldering multiple myeloma

    If approved, Darzalex would be the first therapy approved in the EU for SMM

    - PMLiVE

    Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

    The reference medicine holds approvals for multiple HER2-positive breast cancer indications

    - PMLiVE

    Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

    Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

    EU flag

    Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

    There is currently only one treatment authorised for the ultra-rare genetic blistering disease

    EU flag

    CHMP recommends Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

    Approximately 480,000 cases of the mosquito-borne viral disease were reported globally in 2024

    - PMLiVE

    Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy

    The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

    - PMLiVE

    MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy

    The severe neuromuscular disease affects approximately 2,500 people in the UK

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    GSK’s Jemperli receives positive CHMP opinion for expanded endometrial cancer use

    Approximately 121,000 people are diagnosed with primary advanced or recurrent endometrial cancer each year in Europe

    - PMLiVE

    NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

    Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

    - PMLiVE

    MHRA urges companies to prepare for Windsor Framework for medicines

    The new UK-wide arrangements for medicines will come into effect on 1 January 2025

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation

    The neurodegenerative disorder affects an estimated 6.9 million people in Europe

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links